| 心房颤动发病机制及其治疗药物应用评价 |
| |
| 引用本文： | 柳莲,王志勇,梅其炳.心房颤动发病机制及其治疗药物应用评价[J].世界临床药物,2013(10):634-639. |
| |
| 作者姓名： | 柳莲 王志勇 梅其炳 |
| |
| 作者单位： | 中国医药工业研究总院上海医药工业研究院创新药物与制药工艺国家重点实验室,上海200040 |
| |
| 摘 要： | 心房颤动（AF）是临床常见的心律失常。近几十年来，随着人均寿命增加，AF发病率显著上升，且呈现出随年龄增长而增加的趋势。本综述同顾相关发病机制研究，重点分析各药物在AF治疗中的应用评价。
|
| 关 键 词： | 心房颤动 分子生物学 遗传学 机制 药物治疗 |
Underlying mechanisms of atrial fibrillation and its therapeutic progress |
| |
| LIU Lian,WANG Zhi-yong,MEI Qi-bing.Underlying mechanisms of atrial fibrillation and its therapeutic progress[J].WORLD CLINICAL DRUGS,2013(10):634-639. |
| |
| Authors: | LIU Lian WANG Zhi-yong MEI Qi-bing |
| |
| Institution: | State Key Laboratory of New Drug ＆ Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200040, China) |
| |
| Abstract: | Atrial fibrillation （AF） is the most common arrhythmia in clinic. In recent decades, as the extended average lifespan, the incidence olAF is increasing with age. This review describes the mechanism of AF and evaluates the drug therapy in the treatment olAF. |
| |
| Keywords: | atrial fibrillation molecular biology genetics mechanism medication |
| 本文献已被 维普 等数据库收录！ |
